I-Tofacitnib Citrate

Inkcazelo emfutshane:

Igama le-API Isalathiso Inkcazo I-USDMF EU DMF CEP
I-Tofacitnib Citrate Irheumatoid arthritis Endlwini      


Iinkcukacha zeMveliso

Iithegi zeMveliso

IINKCUKACHA ZEMVELISO

Imvelaphi

I-Tofacitinib citrate, eyaziwa ngokuba yi-CP-690550 citrate, i-inhibitor enamandla ye-janus kinase 3 (JAK3), i-hematopoetic cell-restricted cell-restricted tyrosine kinase ebandakanyekayo kwi-signal transduction elawula ukusinda kwe-lymphocyte, ukwanda, ukwahlula, kunye ne-apoptosis. I-inhibition yi-JAK3 ekhethekileyo kunye ne-selectivity 1000-fold more than other non-JAK family kinases. Ngaphandle kokuvimbela i-JAKS (IC50 = 1 nM), i-tofacitinib citrate iphinda ivimbele i-janus kinase 2 (JAK2) kunye ne-janus kinase 1 (JAK1) kunye ne-20- kunye ne-100-fold less in potency ngokulandelanayo. Nangona kunjalo, kuphononongo lwakutsha nje, i-affinities ebophelelayo (i-Ki) ye-tofacitinib citrate ngokubhekiselele kwi-JAK1, i-JAK2, kunye ne-JAK3 zichazwe njenge-1.6 nM, i-21.7 nM, kunye ne-6.5 nM ngokulandelanayo.

Isalathiso

ULalitha Vijayakrishnan, R. Venkataramanan kunye noPalak Gulati. Ukunyanga ukuvuvukala kunye ne-janus kinase inhibitor CP-690,550. Iimpawu kwiiSayensi zePharmacological 2011: 32 (1); 25-34

Imveliso Citation

  • 1. UPanagi I, uJennings E, et al. "I-Salmonella Effector SteE Iguqula i-Mammalian Serine / i-Threonine Kinase GSK3 ibe yi-Tyrosine Kinase kwi-Direct Macrophage Polarization." I-Cell Host Microbe. 2020;27(1):41–53.e6. PMID:31862381
  • 2. McInnes IB, Byers NL, et al. "Ukuthelekiswa kwe-baricitinib, i-upadacitinib, kunye ne-tofacitinib edibeneyo yokulawula umqondiso we-cytokine kwi-leukocyte subpopulations yabantu." I-Arthritis Res Ther. 2019 Agasti 2;21(1):183. PMID:31375130
  • 3. ULiu S, uVerma M, nabanye. "Ukumelana ne-Steroid yohlobo lwe-2 ye-innate lymphoid cells ezivela kwizigulane ezine-asthma enzima: Indima ye-thymic stromal lymphopoietin." J Allergy Clin Immunol. 2018 Jan; 141 (1): 257-268.e6. PMID:28433687
  • 4. UZheng, uLufeng, nabanye. "I-3' UTR ye-pseudogene CYP4Z2P ikhuthaza i-tumor angiogenesis kumdlavuza webele ngokusebenza njenge-ceRNA ye-CYP4Z1." Uphando lomhlaza webele kunye nonyango (2015): 1-14. PMID:25701119

Inkcazo

I-Tofacitinib citrate yi-JAK1 / 2/3 inhibitor efumaneka ngomlomo kunye ne-IC50s ye-1, i-20, kunye ne-112 nM, ngokulandelanayo. I-Tofacitinib citrate ine-antibacterial, i-antifungal kunye nemisebenzi ye-antiviral.

Ugcino

4°C, khusela ekukhanyeni

*Kwi-solvent : -80°C, iinyanga ezi-6; -20°C, inyanga eyi-1 (khusela ekukhanyeni)

 

Ubume beMichiza

I-Tofacitnib Citrate

Idatha yeBiological eNxulumeneyo

I-Tofacitnib Citrate2

Idatha yeBiological eNxulumeneyo

I-Tofacitnib Citrate3

Idatha yeBiological eNxulumeneyo

I-Tofacitnib Citrate4

Idatha yeBiological eNxulumeneyo

I-Tofacitnib Citrate5

Idatha yeBiological eNxulumeneyo

I-Tofacitnib Citrate6

ISIQINISEKISO

2018 GMP-2
原料药GMP证书201811(captopril,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
I-FDA-EIR-Letter-201901

ULAWULO LOMgangatho

Ulawulo lomgangatho1

Isindululo18Iiprojekthi zoVavanyo loBulunga ezivunyiweyo4, kwaye6iiprojekthi ziphantsi kolwamkelo.

Ulawulo lomgangatho2

Inkqubo yolawulo lomgangatho wehlabathi ephucukileyo ibeke isiseko esiluqilima sokuthengisa.

Ulawulo lomgangatho3

Ukongamela umgangatho kuqhuba umjikelo wobomi bemveliso ukuqinisekisa umgangatho kunye nesiphumo sonyango.

Ulawulo lomgangatho4

Iqela leMicimbi yoLawulo lobuGcisa lixhasa iimfuno zomgangatho ngexesha lesicelo kunye nokubhaliswa.

ULAWULO LWEMVELISO

cpf5
cpf6

Korea Countec Bottled Packaging Line

cpf7
cpf8

Taiwan CVC Bottled UkuPakisha Line

cpf9
cpf10

Italy CAM Board Packaging Line

cpf11

Umatshini wokuQinisa iFette waseJamani

cpf12

Japan Viswill Tablet Detector

cpf14-1

I-DCS Control Room

UMQHUBA

Intsebenziswano yamazwe ngamazwe
Intsebenziswano yamazwe ngamazwe
Intsebenziswano yasekhaya
Intsebenziswano yasekhaya

  • Ngaphambili:
  • Okulandelayo:

  • Bhala umyalezo wakho apha kwaye uwuthumele kuthi